Spyre Therapeutics, Inc.
SYRE
$44.07
$4.1810.48%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -1.35% | 12.71% | |||
| Gross Profit | 1.35% | -12.71% | |||
| SG&A Expenses | 7.67% | -1.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 0.50% | 9.54% | |||
| Operating Income | -0.50% | -9.54% | |||
| Income Before Tax | -459.15% | 69.54% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -459.15% | 69.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -459.15% | 69.54% | |||
| EBIT | -0.50% | -9.54% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -362.36% | 69.57% | |||
| Normalized Basic EPS | -349.87% | 76.09% | |||
| EPS Diluted | -362.36% | 69.57% | |||
| Normalized Diluted EPS | -349.87% | 76.09% | |||
| Average Basic Shares Outstanding | 24.29% | 0.13% | |||
| Average Diluted Shares Outstanding | 24.29% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||